Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the national flag of Canada alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share

Our COVID-19 Response Efforts

ohnson & Johnson has been actively engaged in fighting pandemics for over a century. We have done it before, and we will do it again.

With our global reach comes a responsibility and unique ability to leverage our deep scientific expertise and extensive partnerships to take on this challenge. Our more than 130,000 employees around the world mobilized with urgency to address the critical needs of families, communities and healthcare providers around the world.

Our commitment to families around the world doesn’t change in a time of crisis: we’ll never stop taking care of you.

Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Latest announcements on Johnson & Johnson’s efforts to address the pandemic and media resources.

COVID-19 Timeline

Since the early days of the outbreak, Johnson & Johnson has been working with industry partners, governments and health authorities to help end the fast-moving COVID-19 pandemic through the development of a possible preventive vaccine candidate against SARS-CoV-2.

February 27, 2021

U.S. FDA authorizes single-dose Janssen COVID-19 vaccine for emergency use

February 19, 2021

Emergency Use Listing submitted to the World Health Organization

February 16, 2021

European Conditional Marketing Authorization Application submitted to the EMA

February 4, 2021

Application submitted to the U.S. FDA for Emergency Use Authorization

November 15, 2020

Initiation of ENSEMBLE 2 clinical trial

September 21, 2020

Initiation of Phase 3 ENSEMBLE clinical trial

July 30, 2020

Preclinical data published in Nature shows J&J’s investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection.

July 22, 2020

First-in-human Phase 1/2a clinical trial commenced.

June 10, 2020

J&J announces acceleration of its COVID-19 vaccine candidate: Phase 1/2a clinical trial to begin in second half of July.

April 23, 2020

J&J enters into a collaboration with Emergent BioSolutions, Inc., to support the manufacturing of its lead investigational COVID-19 vaccine candidate.

March 30, 2020

J&J announces a lead vaccine candidate will move into trials and pledges to supply 1B vaccines worldwide for emergency pandemic use. BARDA and J&J commit $1B to vaccine R&D.

March 27, 2020

J&J and the Johnson & Johnson Foundation announce a $50 million commitment to support frontline health workers battling COVID-19.

March 11, 2020

WHO declares the COVID-19 outbreak a pandemic.

February 26, 2020

The first case of COVID-19 was reported in South America, marking the spread of the disease to six of seven continents.

February 23, 2020

Europe has its first major outbreak of COVID-19, in the Lombardy region of northern Italy

February 18, 2020

J&J announces expanded collaboration with U.S. Department of Health & Human Services to accelerate discovery of potential COVID-19 treatments.

February 11, 2020

J&J announces collaboration with U.S. Department of Health & Human Services to accelerate development of a potential COVID-19 vaccine.

February 11, 2020

COVID-19 is announced as the official name of the disease caused by novel coronavirus. The virus is named SARS-CoV-2.

February 1, 2020

First death linked to 2019-nCoV was reported outside of China, in the Philippines.

January 30, 2020

WHO declares the 2019-nCoV outbreak a public health emergency of international concern (PHEIC).

January 12, 2020

J&J initiates efforts to develop a vaccine candidate against 2019-nCoV and to broadly collaborate with others to screen a library of antiviral molecules.

January 11, 2020

First death linked to 2019-nCoV.

January 7, 2020

WHO announces they have identified a new virus named 2019-nCoV, also known as Wuhan coronavirus. It is from the CoV family, which includes SARS and the common cold.

December 31, 2019

China alerted the World Health Organization (WHO) to several cases of pneumonia in Wuhan. The virus is unknown.

February 27, 2021

February 19, 2021

February 16, 2021

February 4, 2021

November 15, 2020

September 21, 2020

July 30, 2020

July 22, 2020

June 10, 2020

April 23, 2020

March 30, 2020

March 27, 2020

March 11, 2020

February 26, 2020

February 23, 2020

February 18, 2020

February 11, 2020

February 11, 2020

February 1, 2020

January 30, 2020

January 12, 2020

January 11, 2020

January 7, 2020

December 31, 2019

More From Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue